#USA #Xeris Pharmaceuticals #Gvoke VialDx #American Regent #Shirley, NY

American Regent® Launches Gvoke VialDx™ (Glucagon Injection)

On August 27, 2025, American Regent, Inc.® made an exciting announcement concerning the launch of Gvoke VialDx™ (glucagon injection), now available for commercial use. This innovative product promises to significantly improve the diagnostic processes in healthcare, particularly during radiologic examinations.

Gvoke VialDx is a ready-to-dilute liquid glucagon developed as a gastrointestinal motility inhibitor, specifically indicated for intravenous use. This medication is designed to temporarily halt movement in the gastrointestinal tract for more precise imaging during diagnostic procedures in adult patients. The product represents a breakthrough in the ease of use and effectiveness of glucagon injections, which have traditionally been administered in a more complex form.

The successful development and rollout of Gvoke VialDx are the result of a strategic partnership between American Regent and Xeris Pharmaceuticals, Inc. Under this collaboration, Xeris will oversee the supply of the product while American Regent takes charge of its commercialization within the United States. Joann Gioia, Vice President and Chief Commercial Officer at American Regent, shared her enthusiasm for the product and the partnership, emphasizing how Gvoke VialDx aligns with the company’s mission to provide hospitals with essential medicines that improve patient care.

According to Kevin McCulloch, President and COO of Xeris, the launch is a watershed moment for both companies, affirming the importance of Gvoke VialDx as the first liquid glucagon made available to aid diagnostic efforts. The launch not only fulfills an unmet need within the medical community but also underscores American Regent's reputation as a reliable provider of high-quality, sterile injectable products appropriate for intense healthcare settings.

Gvoke VialDx will be sold in 1-count or 10-count packages, each containing 1 mg per 0.2 mL single-dose vials. The product is ready for immediate distribution, with orders available through wholesalers, distributors, or directly from the American Regent Customer Support Group.

Safety and Precautions

While the benefits of Gvoke VialDx are numerous, American Regent underscores the importance of understanding the associated safety information. The product comes with several contraindications, including for patients with pheochromocytoma, insulinoma, and prior hypersensitivity reactions to glucagon or any of its excipients. Serious hypersensitivity reactions, including anaphylactic shock, have been noted in some patients; healthcare professionals are advised to watch for symptoms and to take immediate action when necessary.

There are also precautions to consider for patients with pre-existing cardiac conditions or diabetes mellitus. Gvoke VialDx can provoke reactions, including increased blood pressure, heart rate, and changes in blood glucose levels, necessitating close monitoring during administration.

Overall, Gvoke VialDx is positioned to enhance diagnostic capabilities for healthcare providers, offering not just a new tool in the medical arsenal but also contributing to a paradigm shift in the approach to patient care regarding glucose management and gastrointestinal studies.

Commitment to Excellence

American Regent has been a leader in the pharmaceutical industry for over 50 years, focusing on the development, manufacture, and supply of high-quality injectables. With a commitment to U.S.-based manufacturing and significant investments aimed at expanding their production capabilities, American Regent ensures timely and reliable access to crucial medications.

In addition to Gvoke VialDx, American Regent offers a range of injectable solutions to healthcare professionals, including crucial treatments for iron deficiency and other critical medical needs. For continuous updates and information on their products, medical practitioners and patients can visit American Regent’s website.

In conclusion, the release of Gvoke VialDx marks an important milestone that demonstrates the ongoing dedication of American Regent and Xeris Pharmaceuticals to advancing healthcare through innovative solutions, ultimately aiming toward improved patient outcomes in the diagnosis and treatment of various medical conditions.